An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

Boehringer Ingelheim, IP Group, UK Respiratory Gene Therapy Consortium, and OXB launched the first-in-human clinical trial, known as LENTICLAIR 1.

A discovery offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe. Scientists have pinpointed proteins in ...

The global Cystic Fibrosis Market is valued at $10.4 billion in 2023 and is projected to reach $55.4 billion by 2032, ...

Q4 2024 Management View CEO Krish Krishnan highlighted 2024 as a strong year, driven by the continued success of the VYJUVEK launch in the U.S., which is tracking as a top-tier rare disease launch. He ...

Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023Full year revenues increased 473% to $290.5 million versus ...

Despite the existence of numerous clinical practice guidelines (CPGs) for cystic fibrosis (CF), there is limited understanding of their credibility and consistency. This systematic review aims to ...

Findings from a new study highlight key differences in the gut microbiome of infants with cystic fibrosis (CF) compared to that of healthy infants, and how these alterations may adversely affect their ...

The form of abuse that causes a parent to subject her child to years of unnecessary medical intrusions is known as Munchausen syndrome by proxy.

The effect of cystic fibrosis on many organs and the frequent lung infections means that it is mostly diagnosed in childhood.

With 103 lung transplants and one heart-lung transplant in 2024, MHH is the leader in the Eurotransplant network. The lung transplant team relies on minimally invasive procedures and innovative ...